Is CG Oncology, Inc. (CGON) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 14.2% / 30% | 0.0% / 30% | 740.87% / 5% | ✗ NOT HALAL |
| DJIM | 0.1% / 33% | 14.2% / 33% | 0.0% / 33% | 740.87% / 5% | ✗ NOT HALAL |
| MSCI | 0.9% / 33% | 93.8% / 33% | 0.1% / 33% | 740.87% / 5% | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 14.2% / 33% | 0.0% / 33% | 740.87% / 5% | ✗ NOT HALAL |
| FTSE | 0.9% / 33% | 93.8% / 33% | 0.1% / 50% | 740.87% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -2097.3% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -21.7% | |
| Return on Assets (ROA) | -15.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$132M |
| Free Cash Flow | -$132M |
| Total Debt | $7M |
| Debt-to-Equity | 0.9 |
| Current Ratio | 24.6 |
| Total Assets | $792M |
Price & Trading
| Last Close | $66.67 |
| 50-Day MA | $58.04 |
| 200-Day MA | $40.86 |
| Avg Volume | 1.3M |
| Beta | 1.2 |
|
52-Week Range
$14.80
| |
About CG Oncology, Inc. (CGON)
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CG Oncology, Inc. (CGON) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CG Oncology, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CG Oncology, Inc.'s debt ratio?
CG Oncology, Inc.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.9%.
What are CG Oncology, Inc.'s key financial metrics?
CG Oncology, Inc. has a market capitalization of $5.5B, and revenue of $4M. Return on equity stands at -21.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.